PMC:7274968 / 4675-4848 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"75","span":{"begin":102,"end":104},"obj":"Gene"},{"id":"80","span":{"begin":88,"end":96},"obj":"Species"},{"id":"87","span":{"begin":74,"end":87},"obj":"Disease"},{"id":"88","span":{"begin":106,"end":112},"obj":"Disease"},{"id":"89","span":{"begin":121,"end":125},"obj":"Disease"}],"attributes":[{"id":"A75","pred":"tao:has_database_id","subj":"75","obj":"Gene:2069"},{"id":"A80","pred":"tao:has_database_id","subj":"80","obj":"Tax:9606"},{"id":"A87","pred":"tao:has_database_id","subj":"87","obj":"MESH:D001943"},{"id":"A88","pred":"tao:has_database_id","subj":"88","obj":"MESH:D009369"},{"id":"A89","pred":"tao:has_database_id","subj":"89","obj":"MESH:D002285"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The use of upfront endocrine therapy to delay radiotherapy initiation for breast cancer patients with ER+ cancer, either DCIS or invasive, was adopted by 50% of the centers."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T11","span":{"begin":74,"end":80},"obj":"Body_part"}],"attributes":[{"id":"A11","pred":"fma_id","subj":"T11","obj":"http://purl.org/sig/ont/fma/fma9601"}],"text":"The use of upfront endocrine therapy to delay radiotherapy initiation for breast cancer patients with ER+ cancer, either DCIS or invasive, was adopted by 50% of the centers."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T6","span":{"begin":74,"end":80},"obj":"Body_part"}],"attributes":[{"id":"A6","pred":"uberon_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/UBERON_0000310"}],"text":"The use of upfront endocrine therapy to delay radiotherapy initiation for breast cancer patients with ER+ cancer, either DCIS or invasive, was adopted by 50% of the centers."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T32","span":{"begin":74,"end":87},"obj":"Disease"},{"id":"T33","span":{"begin":81,"end":87},"obj":"Disease"},{"id":"T34","span":{"begin":106,"end":112},"obj":"Disease"},{"id":"T35","span":{"begin":121,"end":125},"obj":"Disease"}],"attributes":[{"id":"A32","pred":"mondo_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/MONDO_0007254"},{"id":"A33","pred":"mondo_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A34","pred":"mondo_id","subj":"T34","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A35","pred":"mondo_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/MONDO_0005023"}],"text":"The use of upfront endocrine therapy to delay radiotherapy initiation for breast cancer patients with ER+ cancer, either DCIS or invasive, was adopted by 50% of the centers."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T60","span":{"begin":74,"end":80},"obj":"http://purl.obolibrary.org/obo/UBERON_0000310"},{"id":"T61","span":{"begin":102,"end":104},"obj":"http://purl.obolibrary.org/obo/PR_000007204"}],"text":"The use of upfront endocrine therapy to delay radiotherapy initiation for breast cancer patients with ER+ cancer, either DCIS or invasive, was adopted by 50% of the centers."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T7","span":{"begin":19,"end":28},"obj":"Chemical"}],"attributes":[{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_24621"}],"text":"The use of upfront endocrine therapy to delay radiotherapy initiation for breast cancer patients with ER+ cancer, either DCIS or invasive, was adopted by 50% of the centers."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T16","span":{"begin":74,"end":87},"obj":"Phenotype"},{"id":"T17","span":{"begin":106,"end":112},"obj":"Phenotype"}],"attributes":[{"id":"A16","pred":"hp_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/HP_0003002"},{"id":"A17","pred":"hp_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"The use of upfront endocrine therapy to delay radiotherapy initiation for breast cancer patients with ER+ cancer, either DCIS or invasive, was adopted by 50% of the centers."}

{"project":"LitCovid-sentences","denotations":[{"id":"T38","span":{"begin":0,"end":173},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The use of upfront endocrine therapy to delay radiotherapy initiation for breast cancer patients with ER+ cancer, either DCIS or invasive, was adopted by 50% of the centers."}